NS Partners Ltd reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 40.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,131 shares of the biopharmaceutical company’s stock after selling 89,107 shares during the period. NS Partners Ltd’s holdings in Pfizer were worth $4,721,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PFE. HC Financial Advisors Inc. purchased a new position in shares of Pfizer during the 4th quarter worth about $2,685,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Pfizer by 15.0% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 3,082,158 shares of the biopharmaceutical company’s stock worth $111,636,000 after acquiring an additional 402,638 shares during the period. Dixon Hubard Feinour & Brown Inc. VA lifted its holdings in shares of Pfizer by 1.5% during the 4th quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 130,566 shares of the biopharmaceutical company’s stock worth $4,729,000 after acquiring an additional 1,925 shares during the period. CNB Bank purchased a new position in shares of Pfizer during the 4th quarter worth about $2,057,000. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Pfizer by 10.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 1,086,886 shares of the biopharmaceutical company’s stock worth $39,367,000 after acquiring an additional 102,521 shares during the period. Institutional investors and hedge funds own 68.95% of the company’s stock.

Shares of NYSE:PFE opened at $43.78 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. Pfizer Inc. has a 52-week low of $33.20 and a 52-week high of $45.81. The company has a market capitalization of $262.34 billion, a price-to-earnings ratio of 16.52, a PEG ratio of 2.23 and a beta of 0.96.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The company had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. During the same quarter last year, the company earned $0.67 earnings per share. Pfizer’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.11%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In other Pfizer news, CEO Ian C. Read sold 486,753 shares of the stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $37.36, for a total value of $18,185,092.08. Following the completion of the sale, the chief executive officer now owns 1,145,693 shares of the company’s stock, valued at $42,803,090.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the sale, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. Insiders sold 761,230 shares of company stock valued at $29,054,690 in the last ninety days. 0.06% of the stock is owned by corporate insiders.

A number of analysts recently issued reports on PFE shares. JPMorgan Chase & Co. reissued a “$37.66” rating on shares of Pfizer in a research report on Wednesday, July 18th. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, July 11th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research report on Tuesday, July 3rd. BMO Capital Markets reissued a “buy” rating and set a $42.00 target price on shares of Pfizer in a research report on Thursday, July 19th. Finally, Bank of America increased their target price on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $42.40.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: Why do company’s buyback their stock?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.